Capecitabine/Tesetaxel Versus Capecitabine/Placebo as Second-line Therapy for Gastric Cancer
Status:
Unknown status
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
This study is being performed to evaluate the efficacy and safety of capecitabine in
combination with tesetaxel versus capecitabine in combination with placebo as second-line
treatment for patients with gastric cancer.